Blessing M Fubara
Examiner (ID: 2724, Phone: (571)272-0594 , Office: P/1613 )
Most Active Art Unit | 1613 |
Art Unit(s) | 1613, 1618, 1615 |
Total Applications | 2265 |
Issued Applications | 1176 |
Pending Applications | 331 |
Abandoned Applications | 758 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 18921330
[patent_doc_number] => 20240024334
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-25
[patent_title] => NOVEL METHODS
[patent_app_type] => utility
[patent_app_number] => 18/481168
[patent_app_country] => US
[patent_app_date] => 2023-10-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18211
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18481168
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/481168 | NOVEL METHODS | Oct 3, 2023 | Pending |
Array
(
[id] => 18980128
[patent_doc_number] => 11905288
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-02-20
[patent_title] => Pyrido[3'',4'':4', 5']pyrrolo[3',2':4,5]imidazole[1,2-c]pyrimidine compounds as CK2 inhibitors
[patent_app_type] => utility
[patent_app_number] => 18/235029
[patent_app_country] => US
[patent_app_date] => 2023-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9955
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18235029
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/235029 | Pyrido[3'',4'':4', 5']pyrrolo[3',2':4,5]imidazole[1,2-c]pyrimidine compounds as CK2 inhibitors | Aug 16, 2023 | Issued |
Array
(
[id] => 18550742
[patent_doc_number] => 20230248742
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-10
[patent_title] => PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE
[patent_app_type] => utility
[patent_app_number] => 18/299493
[patent_app_country] => US
[patent_app_date] => 2023-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5415
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18299493
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/299493 | PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE | Apr 11, 2023 | Pending |
Array
(
[id] => 18338657
[patent_doc_number] => 20230130606
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-27
[patent_title] => METHODS AND COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION
[patent_app_type] => utility
[patent_app_number] => 17/975403
[patent_app_country] => US
[patent_app_date] => 2022-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9324
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17975403
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/975403 | METHODS AND COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION | Oct 26, 2022 | Pending |
Array
(
[id] => 18339501
[patent_doc_number] => 20230131450
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-27
[patent_title] => ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT
[patent_app_type] => utility
[patent_app_number] => 17/973345
[patent_app_country] => US
[patent_app_date] => 2022-10-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36123
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17973345
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/973345 | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT | Oct 24, 2022 | Pending |
Array
(
[id] => 18339221
[patent_doc_number] => 20230131170
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-27
[patent_title] => TOPICAL COMPOSITIONS AND METHODS FOR PHOTODYNAMIC THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/968931
[patent_app_country] => US
[patent_app_date] => 2022-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16852
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -51
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17968931
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/968931 | TOPICAL COMPOSITIONS AND METHODS FOR PHOTODYNAMIC THERAPY | Oct 18, 2022 | Pending |
Array
(
[id] => 18158815
[patent_doc_number] => 20230025407
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-26
[patent_title] => COMPOSITIONS COMPRISING EPHEDRINE OR AN EPHEDRINE SALT AND METHODS OF MAKING AND USING SAME
[patent_app_type] => utility
[patent_app_number] => 17/943185
[patent_app_country] => US
[patent_app_date] => 2022-09-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18965
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 130
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17943185
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/943185 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same | Sep 11, 2022 | Issued |
Array
(
[id] => 18226407
[patent_doc_number] => 20230065401
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => METHODS OF ADMINISTRATION FOR HIGHLY WATER-SOLUBLE SALTS OF A SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKER
[patent_app_type] => utility
[patent_app_number] => 17/865697
[patent_app_country] => US
[patent_app_date] => 2022-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31236
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17865697
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/865697 | METHODS OF ADMINISTRATION FOR HIGHLY WATER-SOLUBLE SALTS OF A SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKER | Jul 14, 2022 | Pending |
Array
(
[id] => 18055512
[patent_doc_number] => 20220386598
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => SANITIZING RINSE BASED ON QUAT-ANIONIC SURFACTANT SYNERGY
[patent_app_type] => utility
[patent_app_number] => 17/810196
[patent_app_country] => US
[patent_app_date] => 2022-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23923
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17810196
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/810196 | SANITIZING RINSE BASED ON QUAT-ANIONIC SURFACTANT SYNERGY | Jun 29, 2022 | Pending |
Array
(
[id] => 18690885
[patent_doc_number] => 20230321047
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => USE OF COMPOUND OR MEDICINAL DERIVATIVE THEREOF IN INHIBITING AIM2 PROTEIN ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 17/837344
[patent_app_country] => US
[patent_app_date] => 2022-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6124
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17837344
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/837344 | Use of compound or medicinal derivative thereof in inhibiting AIM2 protein activity | Jun 9, 2022 | Issued |
Array
(
[id] => 19410519
[patent_doc_number] => 12076310
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-03
[patent_title] => Compounds and methods for the treatment of acute myelogenous leukemia
[patent_app_type] => utility
[patent_app_number] => 17/835545
[patent_app_country] => US
[patent_app_date] => 2022-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 34
[patent_no_of_words] => 21196
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17835545
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/835545 | Compounds and Methods for the Treatment of Acute Myelogenous Leukemia | Jun 7, 2022 | Pending |
Array
(
[id] => 18056338
[patent_doc_number] => 20220387424
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT
[patent_app_type] => utility
[patent_app_number] => 17/805374
[patent_app_country] => US
[patent_app_date] => 2022-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13888
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -34
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17805374
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/805374 | METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | Jun 2, 2022 | Pending |
Array
(
[id] => 17881130
[patent_doc_number] => 20220296607
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-22
[patent_title] => TARGETED TREATMENT OF MATURE T-CELL LYMPHOMA
[patent_app_type] => utility
[patent_app_number] => 17/831248
[patent_app_country] => US
[patent_app_date] => 2022-06-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5558
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 95
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17831248
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/831248 | TARGETED TREATMENT OF MATURE T-CELL LYMPHOMA | Jun 1, 2022 | Pending |
Array
(
[id] => 17836322
[patent_doc_number] => 20220273627
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-01
[patent_title] => TOPICAL COMPOSITION COMPRISING TACROLIMUS
[patent_app_type] => utility
[patent_app_number] => 17/750836
[patent_app_country] => US
[patent_app_date] => 2022-05-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11875
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17750836
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/750836 | TOPICAL COMPOSITION COMPRISING TACROLIMUS | May 22, 2022 | Pending |
Array
(
[id] => 17988919
[patent_doc_number] => 20220354956
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-10
[patent_title] => BIODEGRADABLE DRUG DELIVERY FOR HYDROPHOBIC COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/748464
[patent_app_country] => US
[patent_app_date] => 2022-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31788
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 133
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17748464
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/748464 | BIODEGRADABLE DRUG DELIVERY FOR HYDROPHOBIC COMPOSITIONS | May 18, 2022 | Pending |
Array
(
[id] => 17805704
[patent_doc_number] => 20220257539
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-18
[patent_title] => COMPOSITIONS COMPRISING EPHEDRINE OR AN EPHEDRINE SALT AND METHODS OF MAKING AND USING SAME
[patent_app_type] => utility
[patent_app_number] => 17/738557
[patent_app_country] => US
[patent_app_date] => 2022-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18982
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -45
[patent_words_short_claim] => 113
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17738557
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/738557 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same | May 5, 2022 | Issued |
Array
(
[id] => 18056319
[patent_doc_number] => 20220387405
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => METHODS OF TREATMENT WITH N-((R)-1-(3-CHLOROPYRIDIN-2-YL)-2,2,2-TRIFLUOROETHYL)-2-((S)-2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLINE-5-CARBOXAMIDE
[patent_app_type] => utility
[patent_app_number] => 17/737508
[patent_app_country] => US
[patent_app_date] => 2022-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22388
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17737508
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/737508 | METHODS OF TREATMENT WITH N-((R)-1-(3-CHLOROPYRIDIN-2-YL)-2,2,2-TRIFLUOROETHYL)-2-((S)-2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLINE-5-CARBOXAMIDE | May 4, 2022 | Pending |
Array
(
[id] => 18737764
[patent_doc_number] => 20230346658
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => COMPOSITIONS COMPRISING A POLYPHENOL AND A POLYOXYALKENATED COMPOUND
[patent_app_type] => utility
[patent_app_number] => 17/731802
[patent_app_country] => US
[patent_app_date] => 2022-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7447
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 123
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17731802
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/731802 | COMPOSITIONS COMPRISING A POLYPHENOL AND A POLYOXYALKENATED COMPOUND | Apr 27, 2022 | Pending |
Array
(
[id] => 17774937
[patent_doc_number] => 20220241286
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-04
[patent_title] => TREATMENT OF HIDRADENITIS SUPPURATIVA USING JAK INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/720077
[patent_app_country] => US
[patent_app_date] => 2022-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15987
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17720077
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/720077 | TREATMENT OF HIDRADENITIS SUPPURATIVA USING JAK INHIBITORS | Apr 12, 2022 | Pending |
Array
(
[id] => 17748084
[patent_doc_number] => 20220226287
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-21
[patent_title] => METHODS AND COMPOSITIONS FOR TREATMENT OF PRESBYOPIA, MYDRIASIS, AND OTHER OCULAR DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/708466
[patent_app_country] => US
[patent_app_date] => 2022-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45322
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17708466
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/708466 | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders | Mar 29, 2022 | Issued |